Tag Archives: Gilead Sciences Inc.

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Gilead’s slog downward accelerates; CEO’s growth reassurances need action–now

The News: Gilead Sciences Inc. (Foster City CA) on Tuesday (February 7, 2017) said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror

The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »

Gilead loses record $2.5 billion patent verdict to Merck; so what’s a couple billion when you’ve got plenty more and need to grow–fast?

Gilead Sciences Inc. (Foster City CA) was told by a federal jury to pay $2.54 billion to Merck & Co. (Kenilworth NJ) for using a patented invention as the basis for its… Read more »

Painted as the Latest Pharma Scoundrel, Mylan’s CEO Bresch Isn’t Buying It; She’s Got a Point, Maybe

Last week Mylan pharmaceuticals CEO Heather Bresch seemingly attained a status of villainy synonymous with Lance Armstrong and, more recently, Ryan Lochte, with news stories of its fourfold price increase… Read more »

Wall Street Ponders Brexit’s Impact on Drug, Biotech Stocks

In a historic vote Thursday, Britain has decided to leave the European Union. And, swallowing hard, financial markets around the world are not taking the news very well. Stateside, the Dow… Read more »

New AbbVie Hepatitis C Regimen Shows Strong Cure Rates

Although arriving a little late to the party, AbbVie Inc. (North Chicago) is touting impressive cure rates for its new daily hep C combo as it looks to find a… Read more »

U.S. Prescription Spending to Pass $610 Billion a Year by 2020 Says IMS Health

Spending on prescription drugs in the U.S. rose 12% to a record $425 billion before discounts last year, boosted in part by the introduction of breakthrough medicines for cancer and… Read more »